Trial Profile
A 32-week study of REMUNE vaccine plus HAART therapy for treatment of HIV-1 infection.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2017
Price :
$35
*
At a glance
- Drugs GP120-depleted HIV-1 vaccine (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics
- Acronyms Study816
- 23 Feb 2017 New trial record
- 30 Dec 2016 Results published in the Immune Response BioPharma Media Release